A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer

PURPOSE: Triapine (Vion Pharmaceuticals), a novel inhibitor of the M2 subunit of ribonucleotide reductase (RR), is a potent radiosensitizer. This NCI/CTEP-sponsored phase I study assessed the safety/tolerability of triapine in combination with radiation (RT) in patients with locally advanced pancrea...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Martin, Ludmila Katherine, Grecula, John, Jia, Guang, Wei, Lai, Yang, Xiangyu, Otterson, Gregory A., Wu, Xin, Harper, Erica, Kefauver, Cheryl, Zhou, Bing-Sen, Yen, Yun, Bloomston, Mark, Knopp, Michael, Ivy, S. Percy, Grever, Michael, Bekaii-Saab, Tanios
פורמט: Artigo
שפה:Inglês
יצא לאור: 2012
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3477302/
https://ncbi.nlm.nih.gov/pubmed/22818416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijrobp.2012.06.003
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים